Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer, PMID: 28210141
Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment, PMID: 21843081
Phosphatidylserine: A cancer cell targeting biomarker, PMID: 28870843
Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung Cancer, PMID: 29631965
Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer, PMID: 27265742
Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial, PMID: 31429027
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer, PMID: 29767677
Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer, PMID: 25236982
A Phase I Clinical Trial of the Phosphatidylserine-targeting Antibody Bavituximab in Combination With Radiation Therapy and Capecitabine in the Preoperative Treatment of Rectal Adenocarcinoma, PMID: 28763330
Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts, PMID: 26550540
A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer, PMID: 25826750
Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors, PMID: 21989064
Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases, PMID: 19029986
Targeting phosphatidylserine for Cancer therapy: prospects and challenges, PMID: 32802188
[ 74 As]-Labeled monoclonal antibody against anionic phospholipids, PMID: 20641667
Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis, PMID: 31910414
Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine, PMID: 18316558
Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts, PMID: 26847681
Antibodies to watch in 2014: mid-year update, PMID: 24846335
Hepatitis C therapy: other players in the game, PMID: 21867942
Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer, PMID: 29417044
Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma, PMID: 19887482
Gateways to clinical trials, PMID: 20140276
Antibodies to watch in 2016, PMID: 26651519
Gateways to clinical trials, PMID: 19088949
Effective binding of a phosphatidylserine-targeting antibody to Ebola virus infected cells and purified virions, PMID: 25815346
Click-chemistry strategy for labeling antibodies with copper-64 via a cross-bridged tetraazamacrocyclic chelator scaffold, PMID: 25760776
Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipids, PMID: 25983040
Protective Effect of Anti-Phosphatidylserine Antibody in a Guinea Pig Model of Advanced Hemorrhagic Arenavirus Infection, PMID: 29290843
An orthotopic lung tumor model for image-guided microirradiation in rats, PMID: 20681800
Coincident exposure of phosphatidylethanolamine and anionic phospholipids on the surface of irradiated cells, PMID: 18570887
Catheterized guinea pigs infected with Ebola Zaire virus allows safer sequential sampling to determine the pharmacokinetic profile of a phosphatidylserine-targeting monoclonal antibody, PMID: 23165089
Novel agents and future prospects in the treatment of pancreatic adenocarcinoma, PMID: 23846936
Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation, PMID: 24777853
Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids, PMID: 17785577
Redirecting adenoviruses to tumour cells using therapeutic antibodies: Generation of a versatile human bispecific adaptor, PMID: 26391350
Targeting anionic phospholipids on tumor blood vessels and tumor cells, PMID: 20433993
Phosphatidylserine-Targeting Monoclonal Antibodies Exhibit Distinct Biochemical and Cellular Effects on Anti-CD3/CD28-Stimulated T Cell IFN-γ and TNF-α Production, PMID: 34215655
Phosphatidylserine (PS)-targeting chimeric Interferon (IFN) fusion proteins for anti-tumor applications., PMID:39896467
Expression, purification and characterization of phosphatidylserine-targeting antibodies for biochemical and therapeutic applications., PMID:39824554
Development of betabodies: The next generation of phosphatidylserine targeting agents., PMID:39159812
The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial., PMID:38467639
Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients., PMID:37327319
Phosphatidylserine: The Unique Dual-Role Biomarker for Cancer Imaging and Therapy., PMID:35626139
A Phase 2 Clinical Trial of the Phosphatidylserine-Targeting Antibody Bavituximab in Combination With Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma., PMID:35611264
Phosphatidylserine-Targeting Monoclonal Antibodies Exhibit Distinct Biochemical and Cellular Effects on Anti-CD3/CD28-Stimulated T Cell IFN-γ and TNF-α Production., PMID:34215655
Targeting phosphatidylserine for Cancer therapy: prospects and challenges., PMID:32802188
Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis., PMID:31910414
Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial., PMID:31429027
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer., PMID:29767677
Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung Cancer., PMID:29631965
Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer., PMID:29417044
Protective Effect of Anti-Phosphatidylserine Antibody in a Guinea Pig Model of Advanced Hemorrhagic Arenavirus Infection., PMID:29290843
Phosphatidylserine: A cancer cell targeting biomarker., PMID:28870843
A Phase I Clinical Trial of the Phosphatidylserine-targeting Antibody Bavituximab in Combination With Radiation Therapy and Capecitabine in the Preoperative Treatment of Rectal Adenocarcinoma., PMID:28763330
Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer., PMID:27265742
Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts., PMID:26847681
Antibodies to watch in 2016., PMID:26651519
Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts., PMID:26550540
Redirecting adenoviruses to tumour cells using therapeutic antibodies: Generation of a versatile human bispecific adaptor., PMID:26391350
Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipids., PMID:25983040
A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer., PMID:25826750
Effective binding of a phosphatidylserine-targeting antibody to Ebola virus infected cells and purified virions., PMID:25815346
Click-chemistry strategy for labeling antibodies with copper-64 via a cross-bridged tetraazamacrocyclic chelator scaffold., PMID:25760776
Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer., PMID:25236982
Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer., PMID:28210141
Antibodies to watch in 2014: mid-year update., PMID:24846335
Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation., PMID:24777853
Novel agents and future prospects in the treatment of pancreatic adenocarcinoma., PMID:23846936
Catheterized guinea pigs infected with Ebola Zaire virus allows safer sequential sampling to determine the pharmacokinetic profile of a phosphatidylserine-targeting monoclonal antibody., PMID:23165089
Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors., PMID:21989064
Hepatitis C therapy: other players in the game., PMID:21867942
Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment., PMID:21843081
An orthotopic lung tumor model for image-guided microirradiation in rats., PMID:20681800
Targeting anionic phospholipids on tumor blood vessels and tumor cells., PMID:20433993
Gateways to clinical trials., PMID:20140276
Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma., PMID:19887482
Gateways to clinical trials., PMID:19088949
Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases., PMID:19029986
Coincident exposure of phosphatidylethanolamine and anionic phospholipids on the surface of irradiated cells., PMID:18570887
Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine., PMID:18316558
Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids., PMID:17785577
For research use only. Not for human or drug use.
